中美药物基因组学教育发展概况  

Development of pharmacogenomics education in China and the United States

作　　者：王泉林 孙树森[2] 张伟[1] 曹丹[3] 金一粟[3] WANG Quanlin;SUN Shusen;ZHANG Wei;CAO Dan;JIN Yisu(Department of Clinical Pharmacology,Xiangya Hospital,Central South University,Changsha 410008,Hu nan,China;Western New England University,Springfild 01119,Massachusetts,United States;Center for Teaching and Learning Development,Central South University,Changsha 410000,Hunan,China)

机构地区：[1]中南大学湘雅医院临床药理研究所,湖南长沙410008 [2]美国西新英格兰大学药学院,斯普林菲尔德01119,马萨诸塞州 [3]中南大学教师教学发展中心,湖南长沙410000

出　　处：《中国临床药理学与治疗学》2024年第9期1076-1080,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：湖南省教育教学改革项目(HNJG-2022-0458)。

摘　　要：药物基因组学(pharmacogenomics,PGx)是一门基于功能基因组学与分子药理学的科学,近年来迅速发展并逐步应用于临床,中美两国也因此致力于推动PGx教育的发展。本文对中美PGx教育作一综述,阐明发展PGx教育的重要性,并详细介绍PGx教育在高校和临床中的发展现状以及所面临的挑战。此外,本文就两国PGx教育发展提出一些建议并探讨未来的发展趋势。Pharmacogenomics(PGx)is a science based on functional genomics and molecular pharmacology,which has been rapidly developed and gradually applied to clinical practice in recent years.Therefore,China and the United States are committed to promoting the development of PGx education.This paper reviews PGx education in China and the United States,clarifies the significance of developing PGx education,and provides a detailed introduction to the current development status and challenges of PGx education in universities and clinical settings.Additionally,this paper makes some recommendations for developing PGx education and discusses future development trends in both countries.

关 键 词：药物基因组学 课程开设 专业培养 临床实践 教学设想 

分 类 号：R968[医药卫生—药理学]